Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2023-04-06 Annual Report (ESEF)
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Document d'enregistrement universel 2022
Annual Report (ESEF) Classification · 1% confidence FY 2022
2023-04-06 French
Document d'enregistrement universel 2022
Annual Report (ESEF) Classification · 0% confidence FY 2022
2023-04-06 French
Ipsen obtient une nouvelle PDUFA date de la FDA pour le palovarotène expérimental dans le traitement des personnes atteintes de FOP
Regulatory Filings Classification · 1% confidence The document is a press release dated March 16, 2023, announcing that the FDA has set a new PDUFA date (August 16, 2023) for the experimental drug palovarotene for FOP treatment. It details regulatory interactions (FDA PDUFA date, EMA CHMP review), clinical trial data (MOVE study), and provides company background. This type of announcement, focusing on a specific regulatory milestone or clinical update outside of routine financial reporting (like 10-K or ER), is best classified as a general regulatory announcement or news release. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), and it relates to drug approval progress, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for significant, non-standard corporate news releases, especially those concerning regulatory bodies like the FDA. It is not a Report Publication Announcement (RPA) because it is the primary news release detailing the event, not just announcing the publication of an attached report.
2023-03-16 French
Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP
Legal Proceedings Report Classification · 1% confidence The document is a press release from Ipsen dated March 16, 2023, announcing that the FDA has set a PDUFA date (August 16, 2023) for their resubmitted New Drug Application (NDA) for palovarotene. It discusses regulatory milestones (FDA review, EMA re-examination request) and provides clinical trial updates. This type of announcement, focusing on regulatory progress and key clinical/business updates outside of routine financial reporting (like quarterly results or annual reports), is best classified as a general Regulatory Filing or announcement, as it doesn't fit the specific definitions for ER, IR, 10-K, or LTR (legal proceedings). Since it is a specific announcement about regulatory action and progress, and not a general 'Report Publication Announcement' (RPA) stating another report is attached, the most appropriate general category is Regulatory Filings (RNS), which serves as a broad category for significant, non-standard corporate announcements.
2023-03-16 English
Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital
Regulatory Filings Classification · 1% confidence The document is titled "Monthly information relative to the total number of voting rights and shares composing the share capital" and references French regulatory articles (AMF). It provides a table detailing the total number of shares and voting rights as of a specific date (February 28, 2023). This content directly relates to the structure of voting rights and share capital, which is a specific type of regulatory disclosure. While it is a monthly update, it is not a standard quarterly/interim financial report (IR) or an annual report (10-K). It is a specific disclosure related to share capital and voting rights. Among the provided codes, none perfectly match a 'Monthly Voting Rights Disclosure'. However, it is a specific regulatory filing concerning capital structure and ownership rights. Given the options, it is closest to a general regulatory filing (RNS) or perhaps a specific disclosure related to capital changes (SHA), but SHA is usually for new issues/splits. Since it is a mandatory monthly disclosure about the total number of shares and voting rights, it fits best under the general 'Regulatory Filings' (RNS) category as a specific, non-financial periodic disclosure, or potentially a 'Declaration of Voting Results & Voting Rights Announcements' (DVA) if interpreted broadly, but DVA usually refers to the *results* of a vote, not the ongoing count. Given the nature of mandatory periodic disclosure on share capital structure, RNS is the most appropriate fallback for a specific regulatory notice that doesn't fit the other categories like DIV, SHA, or DIRS.
2023-03-10 English
Ipsen SA - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Share Issue/Capital Change Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of a specific date (February 28, 2023). This content directly relates to changes in the capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it specifically details the composition of the capital and voting rights, SHA is the most precise fit among the defined categories, as it reflects a change or update to the share capital structure.
2023-03-10 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.